These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 21103666)

  • 1. Rivaroxaban and false positive lupus anticoagulant testing.
    Merriman E; Kaplan Z; Butler J; Malan E; Gan E; Tran H
    Thromb Haemost; 2011 Feb; 105(2):385-6. PubMed ID: 21103666
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time.
    van Os GM; de Laat B; Kamphuisen PW; Meijers JC; de Groot PG
    J Thromb Haemost; 2011 Aug; 9(8):1657-9. PubMed ID: 21668740
    [No Abstract]   [Full Text] [Related]  

  • 3. Lupus anticoagulant diagnosis in activated partial thromboplastin time mixing test: optimization of the index of circulating anticoagulant cut-off value.
    Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N; Suzuki T; Aoki T
    Clin Lab; 2014; 60(12):2115-8. PubMed ID: 25651752
    [No Abstract]   [Full Text] [Related]  

  • 4. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome.
    Góralczyk T; Iwaniec T; Wypasek E; Undas A
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):473-5. PubMed ID: 25402189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
    Tichelaar V; de Jong H; Nijland H; Kluin-Nelemans H; Meijer K; Mulder A
    Thromb Haemost; 2011 Nov; 106(5):990-2. PubMed ID: 21901233
    [No Abstract]   [Full Text] [Related]  

  • 6. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
    Moore GW; Rangarajan S; Savidge GF
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
    Ząbczyk M; Kopytek M; Natorska J; Undas A
    Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban, the first oral, direct factor Xa inhibitor.
    Fassiadis N
    Expert Opin Pharmacother; 2009 Dec; 10(18):2945-6. PubMed ID: 19925048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there evidence for persistent or transient positive lupus anticoagulants according to the degree of prolongation of clotting tests?
    Devreese KM
    Thromb Res; 2008; 122(4):576-9. PubMed ID: 18304615
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).
    Romualdi E; Donadini MP; Ageno W
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):841-4. PubMed ID: 21809964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
    Favaloro EJ; Mohammed S; Curnow J; Pasalic L
    Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of rivaroxaban-treated patients.
    Palareti G; Ageno W; Ferrari A; Filippi A; Imberti D; Pengo V; Rubboli A; Toni D
    Expert Opin Pharmacother; 2013 Apr; 14(5):655-67. PubMed ID: 23414291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.
    Harenberg J; Marx S; Erdle S; Krämer R
    Expert Rev Hematol; 2012 Feb; 5(1):107-13. PubMed ID: 22272710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for thromboprophylaxis.
    ten Cate H; Hamulyak K
    N Engl J Med; 2008 Nov; 359(20):2174-5; author reply 2176. PubMed ID: 19009676
    [No Abstract]   [Full Text] [Related]  

  • 17. ISTH guidelines on lupus anticoagulant testing.
    Pengo V
    Thromb Res; 2012 Oct; 130 Suppl 1():S76-7. PubMed ID: 23026672
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral anticoagulation with rivaroxaban during pregnancy: a case report.
    Königsbrügge O; Langer M; Hayde M; Ay C; Pabinger I
    Thromb Haemost; 2014 Dec; 112(6):1323-4. PubMed ID: 25055834
    [No Abstract]   [Full Text] [Related]  

  • 19. Lupus anticoagulant syndrome: case report.
    Mwanda OW
    East Afr Med J; 1998 Oct; 75(10):619-20. PubMed ID: 10065201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in venous thromboembolism].
    Qin L; Lu WX
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 May; 36(5):372-4. PubMed ID: 24047815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.